True hyponatremia in the setting of pegasparagase-induced hypertriglyceridemia: A case report

Clin Chim Acta. 2022 Jun 1:531:68-70. doi: 10.1016/j.cca.2022.02.017. Epub 2022 Mar 10.

Abstract

Pegasparagase (PEG-Asparaginase) induced hypertriglyceridemia is rare in the treatment of lymphoblastic lymphoma in children. We present a case of PEG-asparaginase induced hypertriglyceridemia that was incidentally identified and suspicion of its interference with sodium measurement in the clinical laboratory. The use of a direct ion selective method clarified the presence of true hyponatremia. The patient was treated with an oral Fenofibrate therapy which resolved the hypertriglyceridemia. This case highlights that PEG-asparaginanse and Olazanpine can induce hypertriglyceridemia in acute lymphoblastic leukemia and it may be useful to obtain baseline triglyceride measurements for these patients.

Keywords: Asparaginase; Hypertriglyceridemia; Hyponatremia; Pegasparagase.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Asparaginase / adverse effects
  • Child
  • Humans
  • Hypertriglyceridemia* / chemically induced
  • Hypertriglyceridemia* / complications
  • Hypertriglyceridemia* / drug therapy
  • Hyponatremia* / chemically induced
  • Hyponatremia* / drug therapy
  • Polyethylene Glycols / adverse effects
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / pathology

Substances

  • Antineoplastic Agents
  • Polyethylene Glycols
  • Asparaginase